Welcome to our dedicated page for MoonLake Immunotherapeutics news (Ticker: MLTX), a resource for investors and traders seeking the latest updates and insights on MoonLake Immunotherapeutics stock.
MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biotech pioneer advancing nanobody-based therapies for inflammatory skin and joint conditions. This page aggregates official announcements, trial updates, and strategic developments for stakeholders tracking the company's progress.
Investors and researchers will find verified updates on clinical milestones, regulatory filings, and partnership announcements. Key content includes trial result disclosures, R&D pipeline advancements, and executive commentary – all essential for assessing MLTX's position in autoimmune therapeutics.
Regular updates cover three focus areas: clinical trial phases for lead candidates, regulatory pathway developments, and strategic collaborations enhancing nanobody platform applications. This centralized resource eliminates the need to track multiple channels for material updates.
Bookmark this page for streamlined access to MoonLake's latest scientific advancements and corporate announcements. Check back frequently for real-time updates on innovations targeting IL-17 pathways through next-generation biologics.
MoonLake Immunotherapeutics has launched the Phase 3 VELA program, testing the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS). The program aims to enroll 800 patients and is expected to report its topline primary endpoint at week 16 by mid-2025. Sonelokimab targets inflammation by inhibiting IL-17A/A, IL-17A/F, and IL-17F/F dimers. The Phase 3 program, following the successful Phase 2 MIRA trial, will use HiSCR75 as its primary endpoint. The trial will last 52 weeks, with an open-label extension up to two years.
MoonLake Immunotherapeutics reported positive feedback on the regulatory path for the Phase 3 program of Nanobody® sonelokimab, significant improvements in ARGO Phase 2 trial, and plans to commence four additional clinical trials across dermatology and rheumatology. The company ended Q1 2024 with $547.1 million in cash and expects a cash runway to the end of 2026.
FAQ
What is the current stock price of MoonLake Immunotherapeutics (MLTX)?
What is the market cap of MoonLake Immunotherapeutics (MLTX)?
